APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

CD11b Antibody

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global CD11b Antibody Market Analysis and Forecast 2026-2032

Report ID 173975620219 December 2025209 pages

Choose your research edition.

Industry ResearchCD11b Antibody Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal CD11b Antibody Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal CD11b Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CD11b Antibody Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal CD11b Antibody Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global CD11b Antibody market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for CD11b Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for CD11b Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for CD11b Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for CD11b Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of CD11b Antibody include Merck, Boster Biological Technology, United States Biological, Synaptic, Santa Cruz Biotechnology, Proteintech, Miltenyi Biotec, Hytest and GeneTex, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for CD11b Antibody, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of CD11b Antibody, also provides the revenue of main regions and countries. Of the upcoming market potential for CD11b Antibody, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the CD11b Antibody revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global CD11b Antibody market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for CD11b Antibody revenue, projected growth trends, production technology, application and end-user industry.

CD11b Antibody Segment by Company

Merck

Boster Biological Technology

United States Biological

Synaptic

Santa Cruz Biotechnology

Proteintech

Miltenyi Biotec

Hytest

GeneTex

FineTest

EXBIO

Everest Biotech

Bio-Rad

BioLegend

Bio X Cell

Beckman Coulter

Atlas Antibodies

CD11b Antibody Segment by Type

Polyclonal

Monoclonal

CD11b Antibody Segment by Application

Western Blot

Flow Cytometry

Enzyme Linked Immunosorbent Assay

Immunoprecipitation

Immunofluorescence

Others

CD11b Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CD11b Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CD11b Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CD11b Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of CD11b Antibody in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of CD11b Antibody company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CD11b Antibody revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global CD11b Antibody Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Polyclonal Major Player Table 3. Monoclonal Major Player Table 4. Global CD11b Antibody Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Western Blot Major Player Table 6. Flow Cytometry Major Player Table 7. Enzyme Linked Immunosorbent Assay Major Player Table 8. Immunoprecipitation Major Player Table 9. Immunofluorescence Major Player Table 10. Others Major Player Table 11. CD11b Antibody Industry Trends Table 12. CD11b Antibody Industry Drivers Table 13. CD11b Antibody Industry Opportunities and Challenges Table 14. CD11b Antibody Industry Restraints Table 15. Global CD11b Antibody Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global CD11b Antibody Market Size by Region (2021-2026) & (US$ Million) Table 17. Global CD11b Antibody Market Share by Region (2021-2026) Table 18. Global CD11b Antibody Market Size by Region (2027-2032) & (US$ Million) Table 19. Global CD11b Antibody Market Share by Region (2027-2032) Table 20. Global CD11b Antibody Revenue by Players (US$ Million) & (2021-2026) Table 21. Global CD11b Antibody Revenue Market Share by Players (2021-2026) Table 22. Global CD11b Antibody Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global CD11b Antibody Key Players Headquarters & Area Served Table 24. Global CD11b Antibody Players, Product Type & Application Table 25. Global CD11b Antibody Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global CD11b Antibody by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global CD11b Antibody Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global CD11b Antibody Revenue by Type (2021-2026) & (US$ Million) Table 30. Global CD11b Antibody Revenue by Type (2027-2032) & (US$ Million) Table 31. Global CD11b Antibody Revenue Market Share by Type (2021-2026) Table 32. Global CD11b Antibody Revenue Market Share by Type (2027-2032) Table 33. Global CD11b Antibody Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global CD11b Antibody Revenue by Application (2021-2026) & (US$ Million) Table 35. Global CD11b Antibody Revenue by Application (2027-2032) & (US$ Million) Table 36. Global CD11b Antibody Revenue Market Share by Application (2021-2026) Table 37. Global CD11b Antibody Revenue Market Share by Application (2027-2032) Table 38. Merck Company Information Table 39. Merck Business Overview Table 40. Merck CD11b Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Merck CD11b Antibody Product Portfolio Table 42. Merck Recent Development Table 43. Boster Biological Technology Company Information Table 44. Boster Biological Technology Business Overview Table 45. Boster Biological Technology CD11b Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Boster Biological Technology CD11b Antibody Product Portfolio Table 47. Boster Biological Technology Recent Development Table 48. United States Biological Company Information Table 49. United States Biological Business Overview Table 50. United States Biological CD11b Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. United States Biological CD11b Antibody Product Portfolio Table 52. United States Biological Recent Development Table 53. Synaptic Company Information Table 54. Synaptic Business Overview Table 55. Synaptic CD11b Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Synaptic CD11b Antibody Product Portfolio Table 57. Synaptic Recent Development Table 58. Santa Cruz Biotechnology Company Information Table 59. Santa Cruz Biotechnology Business Overview Table 60. Santa Cruz Biotechnology CD11b Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Santa Cruz Biotechnology CD11b Antibody Product Portfolio Table 62. Santa Cruz Biotechnology Recent Development Table 63. Proteintech Company Information Table 64. Proteintech Business Overview Table 65. Proteintech CD11b Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Proteintech CD11b Antibody Product Portfolio Table 67. Proteintech Recent Development Table 68. Miltenyi Biotec Company Information Table 69. Miltenyi Biotec Business Overview Table 70. Miltenyi Biotec CD11b Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Miltenyi Biotec CD11b Antibody Product Portfolio Table 72. Miltenyi Biotec Recent Development Table 73. Hytest Company Information Table 74. Hytest Business Overview Table 75. Hytest CD11b Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Hytest CD11b Antibody Product Portfolio Table 77. Hytest Recent Development Table 78. GeneTex Company Information Table 79. GeneTex Business Overview Table 80. GeneTex CD11b Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. GeneTex CD11b Antibody Product Portfolio Table 82. GeneTex Recent Development Table 83. FineTest Company Information Table 84. FineTest Business Overview Table 85. FineTest CD11b Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. FineTest CD11b Antibody Product Portfolio Table 87. FineTest Recent Development Table 88. EXBIO Company Information Table 89. EXBIO Business Overview Table 90. EXBIO CD11b Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. EXBIO CD11b Antibody Product Portfolio Table 92. EXBIO Recent Development Table 93. Everest Biotech Company Information Table 94. Everest Biotech Business Overview Table 95. Everest Biotech CD11b Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Everest Biotech CD11b Antibody Product Portfolio Table 97. Everest Biotech Recent Development Table 98. Bio-Rad Company Information Table 99. Bio-Rad Business Overview Table 100. Bio-Rad CD11b Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Bio-Rad CD11b Antibody Product Portfolio Table 102. Bio-Rad Recent Development Table 103. BioLegend Company Information Table 104. BioLegend Business Overview Table 105. BioLegend CD11b Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. BioLegend CD11b Antibody Product Portfolio Table 107. BioLegend Recent Development Table 108. Bio X Cell Company Information Table 109. Bio X Cell Business Overview Table 110. Bio X Cell CD11b Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Bio X Cell CD11b Antibody Product Portfolio Table 112. Bio X Cell Recent Development Table 113. Beckman Coulter Company Information Table 114. Beckman Coulter Business Overview Table 115. Beckman Coulter CD11b Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Beckman Coulter CD11b Antibody Product Portfolio Table 117. Beckman Coulter Recent Development Table 118. Atlas Antibodies Company Information Table 119. Atlas Antibodies Business Overview Table 120. Atlas Antibodies CD11b Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Atlas Antibodies CD11b Antibody Product Portfolio Table 122. Atlas Antibodies Recent Development Table 123. North America CD11b Antibody Revenue by Type (2021-2026) & (US$ Million) Table 124. North America CD11b Antibody Revenue by Type (2027-2032) & (US$ Million) Table 125. North America CD11b Antibody Revenue by Application (2021-2026) & (US$ Million) Table 126. North America CD11b Antibody Revenue by Application (2027-2032) & (US$ Million) Table 127. North America CD11b Antibody Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 128. North America CD11b Antibody Revenue by Country (2021-2026) & (US$ Million) Table 129. North America CD11b Antibody Revenue by Country (US$ Million) & (2027-2032) Table 130. Europe CD11b Antibody Revenue by Type (2021-2026) & (US$ Million) Table 131. Europe CD11b Antibody Revenue by Type (2027-2032) & (US$ Million) Table 132. Europe CD11b Antibody Revenue by Application (2021-2026) & (US$ Million) Table 133. Europe CD11b Antibody Revenue by Application (2027-2032) & (US$ Million) Table 134. Europe CD11b Antibody Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 135. Europe CD11b Antibody Revenue by Country (2021-2026) & (US$ Million) Table 136. Europe CD11b Antibody Revenue by Country (US$ Million) & (2027-2032) Table 137. China CD11b Antibody Revenue by Type (2021-2026) & (US$ Million) Table 138. China CD11b Antibody Revenue by Type (2027-2032) & (US$ Million) Table 139. China CD11b Antibody Revenue by Application (2021-2026) & (US$ Million) Table 140. China CD11b Antibody Revenue by Application (2027-2032) & (US$ Million) Table 141. Asia CD11b Antibody Revenue by Type (2021-2026) & (US$ Million) Table 142. Asia CD11b Antibody Revenue by Type (2027-2032) & (US$ Million) Table 143. Asia CD11b Antibody Revenue by Application (2021-2026) & (US$ Million) Table 144. Asia CD11b Antibody Revenue by Application (2027-2032) & (US$ Million) Table 145. Asia CD11b Antibody Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 146. Asia CD11b Antibody Revenue by Region (US$ Million) & (2021-2026) Table 147. Asia CD11b Antibody Revenue by Region (US$ Million) & (2027-2032) Table 148. SAMEA CD11b Antibody Revenue by Type (2021-2026) & (US$ Million) Table 149. SAMEA CD11b Antibody Revenue by Type (2027-2032) & (US$ Million) Table 150. SAMEA CD11b Antibody Revenue by Application (2021-2026) & (US$ Million) Table 151. SAMEA CD11b Antibody Revenue by Application (2027-2032) & (US$ Million) Table 152. SAMEA CD11b Antibody Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 153. SAMEA CD11b Antibody Revenue by Country (2021-2026) & (US$ Million) Table 154. SAMEA CD11b Antibody Revenue by Country (US$ Million) & (2027-2032) Table 155. Research Programs/Design for This Report Table 156. Authors List of This Report Table 157. Secondary Sources Table 158. Primary Sources List of Figures Figure 1. CD11b Antibody Image Figure 2. Global CD11b Antibody Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CD11b Antibody Market Size Share 2021 VS 2025 VS 2032 Figure 4. Polyclonal Image Figure 5. Monoclonal Image Figure 6. Global CD11b Antibody Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global CD11b Antibody Market Size Share 2021 VS 2025 VS 2032 Figure 8. Western Blot Image Figure 9. Flow Cytometry Image Figure 10. Enzyme Linked Immunosorbent Assay Image Figure 11. Immunoprecipitation Image Figure 12. Immunofluorescence Image Figure 13. Others Image Figure 14. Global CD11b Antibody Market Size (US$ Million) & (2021-2032) Figure 15. Global CD11b Antibody Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global CD11b Antibody Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global CD11b Antibody Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global CD11b Antibody Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global CD11b Antibody Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global CD11b Antibody Revenue Market Share by Type (2021-2032) Figure 22. Global CD11b Antibody Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global CD11b Antibody Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global CD11b Antibody Revenue Market Share by Application (2021-2032) Figure 25. North America CD11b Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America CD11b Antibody Revenue Share by Type (2021-2032) Figure 27. North America CD11b Antibody Revenue Share by Application (2021-2032) Figure 28. North America CD11b Antibody Revenue Share by Country (2021-2032) Figure 29. United States CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe CD11b Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe CD11b Antibody Revenue Share by Type (2021-2032) Figure 34. Europe CD11b Antibody Revenue Share by Application (2021-2032) Figure 35. Europe CD11b Antibody Revenue Share by Country (2021-2032) Figure 36. Germany CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China CD11b Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China CD11b Antibody Revenue Share by Type (2021-2032) Figure 46. China CD11b Antibody Revenue Share by Application (2021-2032) Figure 47. Asia CD11b Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia CD11b Antibody Revenue Share by Type (2021-2032) Figure 49. Asia CD11b Antibody Revenue Share by Application (2021-2032) Figure 50. Asia CD11b Antibody Revenue Share by Region (2021-2032) Figure 51. Japan CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA CD11b Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA CD11b Antibody Revenue Share by Type (2021-2032) Figure 59. SAMEA CD11b Antibody Revenue Share by Application (2021-2032) Figure 60. SAMEA CD11b Antibody Revenue Share by Country (2021-2032) Figure 61. Brazil CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt CD11b Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Polyclonal
  • Monoclonal
Applications
  • Western Blot
  • Flow Cytometry
  • Enzyme Linked Immunosorbent Assay
  • Immunoprecipitation
  • Immunofluorescence
  • Others
Companies covered
  • Merck
  • Boster Biological Technology
  • United States Biological
  • Synaptic
  • Santa Cruz Biotechnology
  • Proteintech
  • Miltenyi Biotec
  • Hytest
  • GeneTex
  • FineTest
  • EXBIO
  • Everest Biotech
  • Bio-Rad
  • BioLegend
  • Bio X Cell
  • Beckman Coulter
  • Atlas Antibodies

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 CD11b Antibody Market by Type
  3. 1.2.1 Global CD11b Antibody Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Polyclonal
  5. 1.2.3 Monoclonal
  6. 1.3 CD11b Antibody Market by Application
  7. 1.3.1 Global CD11b Antibody Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Western Blot
  9. 1.3.3 Flow Cytometry
  10. 1.3.4 Enzyme Linked Immunosorbent Assay
  11. 1.3.5 Immunoprecipitation
  12. 1.3.6 Immunofluorescence
  13. 1.3.7 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 CD11b Antibody Market Dynamics
  1. 2.1 CD11b Antibody Industry Trends
  2. 2.2 CD11b Antibody Industry Drivers
  3. 2.3 CD11b Antibody Industry Opportunities and Challenges
  4. 2.4 CD11b Antibody Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global CD11b Antibody Market Perspective (2021-2032)
  2. 3.2 Global CD11b Antibody Growth Trends by Region
  3. 3.2.1 Global CD11b Antibody Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global CD11b Antibody Market Size by Region (2021-2026)
  5. 3.2.3 Global CD11b Antibody Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global CD11b Antibody Revenue by Players
  2. 4.1.1 Global CD11b Antibody Revenue by Players (2021-2026)
  3. 4.1.2 Global CD11b Antibody Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global CD11b Antibody Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global CD11b Antibody Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global CD11b Antibody Key Players Headquarters & Area Served
  7. 4.4 Global CD11b Antibody Players, Product Type & Application
  8. 4.5 Global CD11b Antibody Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global CD11b Antibody Market CR5 and HHI
  11. 4.6.3 2025 CD11b Antibody Tier 1, Tier 2, and Tier 3
5 CD11b Antibody Market Size by Type
  1. 5.1 Global CD11b Antibody Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global CD11b Antibody Revenue by Type (2021-2032)
  3. 5.3 Global CD11b Antibody Revenue Market Share by Type (2021-2032)
6 CD11b Antibody Market Size by Application
  1. 6.1 Global CD11b Antibody Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global CD11b Antibody Revenue by Application (2021-2032)
  3. 6.3 Global CD11b Antibody Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Merck
  2. 7.1.1 Merck Company Information
  3. 7.1.2 Merck Business Overview
  4. 7.1.3 Merck CD11b Antibody Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Merck CD11b Antibody Product Portfolio
  6. 7.1.5 Merck Recent Developments
  7. 7.2 Boster Biological Technology
  8. 7.2.1 Boster Biological Technology Company Information
  9. 7.2.2 Boster Biological Technology Business Overview
  10. 7.2.3 Boster Biological Technology CD11b Antibody Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Boster Biological Technology CD11b Antibody Product Portfolio
  12. 7.2.5 Boster Biological Technology Recent Developments
  13. 7.3 United States Biological
  14. 7.3.1 United States Biological Company Information
  15. 7.3.2 United States Biological Business Overview
  16. 7.3.3 United States Biological CD11b Antibody Revenue and Gross Margin (2021-2026)
  17. 7.3.4 United States Biological CD11b Antibody Product Portfolio
  18. 7.3.5 United States Biological Recent Developments
  19. 7.4 Synaptic
  20. 7.4.1 Synaptic Company Information
  21. 7.4.2 Synaptic Business Overview
  22. 7.4.3 Synaptic CD11b Antibody Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Synaptic CD11b Antibody Product Portfolio
  24. 7.4.5 Synaptic Recent Developments
  25. 7.5 Santa Cruz Biotechnology
  26. 7.5.1 Santa Cruz Biotechnology Company Information
  27. 7.5.2 Santa Cruz Biotechnology Business Overview
  28. 7.5.3 Santa Cruz Biotechnology CD11b Antibody Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Santa Cruz Biotechnology CD11b Antibody Product Portfolio
  30. 7.5.5 Santa Cruz Biotechnology Recent Developments
  31. 7.6 Proteintech
  32. 7.6.1 Proteintech Company Information
  33. 7.6.2 Proteintech Business Overview
  34. 7.6.3 Proteintech CD11b Antibody Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Proteintech CD11b Antibody Product Portfolio
  36. 7.6.5 Proteintech Recent Developments
  37. 7.7 Miltenyi Biotec
  38. 7.7.1 Miltenyi Biotec Company Information
  39. 7.7.2 Miltenyi Biotec Business Overview
  40. 7.7.3 Miltenyi Biotec CD11b Antibody Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Miltenyi Biotec CD11b Antibody Product Portfolio
  42. 7.7.5 Miltenyi Biotec Recent Developments
  43. 7.8 Hytest
  44. 7.8.1 Hytest Company Information
  45. 7.8.2 Hytest Business Overview
  46. 7.8.3 Hytest CD11b Antibody Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Hytest CD11b Antibody Product Portfolio
  48. 7.8.5 Hytest Recent Developments
  49. 7.9 GeneTex
  50. 7.9.1 GeneTex Company Information
  51. 7.9.2 GeneTex Business Overview
  52. 7.9.3 GeneTex CD11b Antibody Revenue and Gross Margin (2021-2026)
  53. 7.9.4 GeneTex CD11b Antibody Product Portfolio
  54. 7.9.5 GeneTex Recent Developments
  55. 7.10 FineTest
  56. 7.10.1 FineTest Company Information
  57. 7.10.2 FineTest Business Overview
  58. 7.10.3 FineTest CD11b Antibody Revenue and Gross Margin (2021-2026)
  59. 7.10.4 FineTest CD11b Antibody Product Portfolio
  60. 7.10.5 FineTest Recent Developments
  61. 7.11 EXBIO
  62. 7.11.1 EXBIO Company Information
  63. 7.11.2 EXBIO Business Overview
  64. 7.11.3 EXBIO CD11b Antibody Revenue and Gross Margin (2021-2026)
  65. 7.11.4 EXBIO CD11b Antibody Product Portfolio
  66. 7.11.5 EXBIO Recent Developments
  67. 7.12 Everest Biotech
  68. 7.12.1 Everest Biotech Company Information
  69. 7.12.2 Everest Biotech Business Overview
  70. 7.12.3 Everest Biotech CD11b Antibody Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Everest Biotech CD11b Antibody Product Portfolio
  72. 7.12.5 Everest Biotech Recent Developments
  73. 7.13 Bio-Rad
  74. 7.13.1 Bio-Rad Company Information
  75. 7.13.2 Bio-Rad Business Overview
  76. 7.13.3 Bio-Rad CD11b Antibody Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Bio-Rad CD11b Antibody Product Portfolio
  78. 7.13.5 Bio-Rad Recent Developments
  79. 7.14 BioLegend
  80. 7.14.1 BioLegend Company Information
  81. 7.14.2 BioLegend Business Overview
  82. 7.14.3 BioLegend CD11b Antibody Revenue and Gross Margin (2021-2026)
  83. 7.14.4 BioLegend CD11b Antibody Product Portfolio
  84. 7.14.5 BioLegend Recent Developments
  85. 7.15 Bio X Cell
  86. 7.15.1 Bio X Cell Company Information
  87. 7.15.2 Bio X Cell Business Overview
  88. 7.15.3 Bio X Cell CD11b Antibody Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Bio X Cell CD11b Antibody Product Portfolio
  90. 7.15.5 Bio X Cell Recent Developments
  91. 7.16 Beckman Coulter
  92. 7.16.1 Beckman Coulter Company Information
  93. 7.16.2 Beckman Coulter Business Overview
  94. 7.16.3 Beckman Coulter CD11b Antibody Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Beckman Coulter CD11b Antibody Product Portfolio
  96. 7.16.5 Beckman Coulter Recent Developments
  97. 7.17 Atlas Antibodies
  98. 7.17.1 Atlas Antibodies Company Information
  99. 7.17.2 Atlas Antibodies Business Overview
  100. 7.17.3 Atlas Antibodies CD11b Antibody Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Atlas Antibodies CD11b Antibody Product Portfolio
  102. 7.17.5 Atlas Antibodies Recent Developments
8 North America
  1. 8.1 North America CD11b Antibody Revenue (2021-2032)
  2. 8.2 North America CD11b Antibody Revenue by Type (2021-2032)
  3. 8.2.1 North America CD11b Antibody Revenue by Type (2021-2026)
  4. 8.2.2 North America CD11b Antibody Revenue by Type (2027-2032)
  5. 8.3 North America CD11b Antibody Revenue Share by Type (2021-2032)
  6. 8.4 North America CD11b Antibody Revenue by Application (2021-2032)
  7. 8.4.1 North America CD11b Antibody Revenue by Application (2021-2026)
  8. 8.4.2 North America CD11b Antibody Revenue by Application (2027-2032)
  9. 8.5 North America CD11b Antibody Revenue Share by Application (2021-2032)
  10. 8.6 North America CD11b Antibody Revenue by Country
  11. 8.6.1 North America CD11b Antibody Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America CD11b Antibody Revenue by Country (2021-2026)
  13. 8.6.3 North America CD11b Antibody Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe CD11b Antibody Revenue (2021-2032)
  2. 9.2 Europe CD11b Antibody Revenue by Type (2021-2032)
  3. 9.2.1 Europe CD11b Antibody Revenue by Type (2021-2026)
  4. 9.2.2 Europe CD11b Antibody Revenue by Type (2027-2032)
  5. 9.3 Europe CD11b Antibody Revenue Share by Type (2021-2032)
  6. 9.4 Europe CD11b Antibody Revenue by Application (2021-2032)
  7. 9.4.1 Europe CD11b Antibody Revenue by Application (2021-2026)
  8. 9.4.2 Europe CD11b Antibody Revenue by Application (2027-2032)
  9. 9.5 Europe CD11b Antibody Revenue Share by Application (2021-2032)
  10. 9.6 Europe CD11b Antibody Revenue by Country
  11. 9.6.1 Europe CD11b Antibody Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe CD11b Antibody Revenue by Country (2021-2026)
  13. 9.6.3 Europe CD11b Antibody Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China CD11b Antibody Revenue (2021-2032)
  2. 10.2 China CD11b Antibody Revenue by Type (2021-2032)
  3. 10.2.1 China CD11b Antibody Revenue by Type (2021-2026)
  4. 10.2.2 China CD11b Antibody Revenue by Type (2027-2032)
  5. 10.3 China CD11b Antibody Revenue Share by Type (2021-2032)
  6. 10.4 China CD11b Antibody Revenue by Application (2021-2032)
  7. 10.4.1 China CD11b Antibody Revenue by Application (2021-2026)
  8. 10.4.2 China CD11b Antibody Revenue by Application (2027-2032)
  9. 10.5 China CD11b Antibody Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia CD11b Antibody Revenue (2021-2032)
  2. 11.2 Asia CD11b Antibody Revenue by Type (2021-2032)
  3. 11.2.1 Asia CD11b Antibody Revenue by Type (2021-2026)
  4. 11.2.2 Asia CD11b Antibody Revenue by Type (2027-2032)
  5. 11.3 Asia CD11b Antibody Revenue Share by Type (2021-2032)
  6. 11.4 Asia CD11b Antibody Revenue by Application (2021-2032)
  7. 11.4.1 Asia CD11b Antibody Revenue by Application (2021-2026)
  8. 11.4.2 Asia CD11b Antibody Revenue by Application (2027-2032)
  9. 11.5 Asia CD11b Antibody Revenue Share by Application (2021-2032)
  10. 11.6 Asia CD11b Antibody Revenue by Country
  11. 11.6.1 Asia CD11b Antibody Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia CD11b Antibody Revenue by Country (2021-2026)
  13. 11.6.3 Asia CD11b Antibody Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA CD11b Antibody Revenue (2021-2032)
  2. 12.2 SAMEA CD11b Antibody Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA CD11b Antibody Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA CD11b Antibody Revenue by Type (2027-2032)
  5. 12.3 SAMEA CD11b Antibody Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA CD11b Antibody Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA CD11b Antibody Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA CD11b Antibody Revenue by Application (2027-2032)
  9. 12.5 SAMEA CD11b Antibody Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA CD11b Antibody Revenue by Country
  11. 12.6.1 SAMEA CD11b Antibody Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA CD11b Antibody Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA CD11b Antibody Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst